A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder
NCT ID: NCT00189800
Last Updated: 2011-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Solifenacin succinate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be able to complete the micturition diary
Exclusion Criteria
* Clinically significant outflow obstruction
* Significant post void residual urine
* Significant stress incontinence
* Urinary tract infection
* Chronic inflammation
* Bladder stones
* Previous pelvic radiation therapy
* Previous or current malignant disease of the pelvic organs
* Uncontrolled narrow angle glaucoma
* Urinary or gastric retention
* Electrostimulation therapy
* Bladder training
* Diabetic neuropathy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Astellas Pharma Korea, Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Prof. Jeong Gu Lee
Role: PRINCIPAL_INVESTIGATOR
Department of Urology, Korea University Anam Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anyang, , South Korea
Bucheon-si, , South Korea
Busan, , South Korea
Cheonan, , South Korea
Daegu, , South Korea
Daejeon, , South Korea
Gwangju, , South Korea
Incheon, , South Korea
Seoul, , South Korea
Suwon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
EU Shi-liang, et al. Efficacy and safety of solifenacin in the treatment of patients with urgency and urge incontinence. Chin J Urol (2009) 30(9); 1-5
Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023 May 9;5(5):CD003781. doi: 10.1002/14651858.CD003781.pub3.
Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, Kim JC, Seo JT, Paick JS, Kim HJ, Na YG, Lee JG. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. Int J Clin Pract. 2008 Nov;62(11):1675-83. doi: 10.1111/j.1742-1241.2008.01898.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
90502/KOoTD01
Identifier Type: -
Identifier Source: org_study_id